Literature DB >> 12853410

Detection of human T-lymphotropic virus (HTLV) tax sequences in New York City blood donors seronegative for HTLV types 1 and 2.

Charlene S Dezzutti1, Patricia C Guenthner, Sylvester Daniel, Ursula Utz, Thania Cabrera, James H Marshall, Celso Bianco, Renu B Lal, Elliot P Cowan.   

Abstract

A potential public health concern is the reported detection of the human T-lymphotropic virus (HTLV) tax gene in the lymphocytes of up to 11% of a low-risk group of New York City blood donors (NYBD). This study aimed to independently confirm the prevalence of HTLV tax sequences in 293 NYBD. All NYBD tested negative for antibodies to HTLV types 1 and 2 and HTLV Tax. HTLV tax sequences were not detected in the NYBD lymphocytes. These data demonstrate the lack of HTLV-1 tax in this group of NYBD at low risk for HTLV infection.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12853410      PMCID: PMC164244          DOI: 10.1128/cdli.10.4.715-717.2003

Source DB:  PubMed          Journal:  Clin Diagn Lab Immunol        ISSN: 1071-412X


  20 in total

1.  Defective and wild-type human T-cell leukemia virus type I proviruses: characterization of gene products and trans-interactions between proviruses.

Authors:  M Shuh; S A Hill; D Derse
Journal:  Virology       Date:  1999-09-30       Impact factor: 3.616

2.  Defective human T-cell leukaemia virus type 1 (HTLV-1) genomes: no evidence in serologically indeterminate german blood donors but new type detected in established cell lines.

Authors:  V A Morozov; H Ellerbrok; C Fleischer; H H Brackmann; G Pauli
Journal:  J Med Virol       Date:  2002-01       Impact factor: 2.327

3.  Indeterminate HTLV serologic results in U.S. blood donors: are they due to HTLV-I or HTLV-II?

Authors:  R F Khabbaz; W Heneine; A Grindon; T M Hartley; G Shulman; J Kaplan
Journal:  J Acquir Immune Defic Syndr (1988)       Date:  1992

4.  Failure to detect evidence of human T-lymphotropic virus (HTLV) type I and type II in blood donors with isolated gag antibodies to HTLV-I/II.

Authors:  R B Lal; D L Rudolph; J E Coligan; S K Brodine; C R Roberts
Journal:  Blood       Date:  1992-07-15       Impact factor: 22.113

5.  HTLV-I and HTLV-II world-wide distribution: reanalysis of 4,832 immunoblot results.

Authors:  M M Madeleine; S Z Wiktor; J J Goedert; A Manns; P H Levine; R J Biggar; W A Blattner
Journal:  Int J Cancer       Date:  1993-05-08       Impact factor: 7.396

6.  Chimeric matrix proteins encoded by defective proviruses with large internal deletions in human T-cell leukemia virus type 1-infected humans.

Authors:  V A Morozov; S Lagaye; G P Taylor; E Matutes; R A Weiss
Journal:  J Virol       Date:  2000-05       Impact factor: 5.103

7.  Serological, epidemiological, and molecular differences between human T-cell lymphotropic virus Type 1 (HTLV-1)-seropositive healthy carriers and persons with HTLV-I Gag indeterminate Western blot patterns from the Caribbean.

Authors:  F Rouet; L Meertens; G Courouble; C Herrmann-Storck; R Pabingui; B Chancerel; A Abid; M Strobel; P Mauclere; A Gessain
Journal:  J Clin Microbiol       Date:  2001-04       Impact factor: 5.948

8.  Differential immune responsiveness to the immunodominant epitopes of regulatory proteins (tax and rex) in human T cell lymphotropic virus type I-associated myelopathy.

Authors:  R B Lal; C Z Giam; J E Coligan; D L Rudolph
Journal:  J Infect Dis       Date:  1994-03       Impact factor: 5.226

Review 9.  An HTLV-I vaccine: why, how, for whom?

Authors:  G de Thé; R Bomford
Journal:  AIDS Res Hum Retroviruses       Date:  1993-05       Impact factor: 2.205

10.  Differential diagnosis of HTLV-I and HTLV-II infections by restriction enzyme analysis of 'nested' PCR products.

Authors:  P W Tuke; P Luton; J A Garson
Journal:  J Virol Methods       Date:  1992-11       Impact factor: 2.014

View more
  1 in total

1.  Can the level of immunosuppression in human immunodeficiency virus-infected patients affect the reliability of human T-cell lymphotropic virus type 2 serological diagnosis?

Authors:  Sylvina Bassani; Carlos Toro; Victoria Jiménez; Berta Rodés; Vincent Soriano
Journal:  Clin Vaccine Immunol       Date:  2006-01
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.